Navigation Links
Lexicon to Provide Second Quarter 2012 Financial Results
Date:7/24/2012

The Woodlands, Texas, July 24, 2012 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), announced today that it will release its second quarter 2012 financial results on Tuesday, July 31, 2012 before the financial markets open. Lexicon management will hold a conference call and webcast to discuss financial results for the quarter and program status at 11:00 a.m. Eastern Time that same day.

The dial-in number for the conference call is 888-645-5785 (within the US/Canada) or 970-300-1531 (international). The conference ID for all callers is 13784620. Investors can access a live webcast of the call at www.lexpharma.com. An archived version of the webcast will be available on Lexicon's corporate website at www.lexpharma.com through August 31, 2012.

About Lexicon

Lexicon is a biopharmaceutical company focused on discovering breakthrough treatments for human disease. Lexicon currently has four drug programs in mid-stage development for diabetes, irritable bowel syndrome, carcinoid syndrome and rheumatoid arthritis, all of which were discovered by Lexicon's research team. Lexicon has used its proprietary gene knockout technology to identify more than 100 promising drug targets. Lexicon has focused drug discovery efforts on these biologically-validated targets to create its extensive pipeline of clinical and preclinical programs. For additional information about Lexicon and its programs, please visit www.lexpharma.com.

Safe Harbor Statement

This press release contains "forward-looking" statements, including statements relating to Lexicon's growth and future operating results, discovery and development of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information. All forward-looking statements are based on management's current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including those relating to Lexicon's ability to successfully conduct preclinical and clinical development of its potential drug candidates, advance additional candidates into preclinical and clinical development, obtain necessary regulatory approvals, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, as well as additional factors relating to manufacturing, intellectual property rights, and the therapeutic or commercial value of its drug candidates, that may cause Lexicon's actual results to be materially different from any future results expressed or implied by such forward-looking statements. Information identifying such important factors is contained under "Risk Factors" in Lexicon's annual report on Form 10-K for the year ended December 31, 2011, as filed with the Securities and Exchange Commission. Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Lexicon Announces Publication of Results of Two Studies of LX4211 in Patients with Type 2 Diabetes in the Journal Clinical Pharmacology & Therapeutics
2. Lexicon Announces Positive Results of LX4211 Phase 2b Trial For Type 2 Diabetes
3. Lexicon Presents Data Regarding the Mechanism of Action and Safety of LX4211 at American Diabetes Association Meeting
4. Lexicon Pharmaceuticals to present at the Jefferies 2012 Global Healthcare Conference
5. Lexicon Receives Funding for Phase 2 Clinical Trial of LX4211 in Type 1 Diabetes
6. Lexicon Pharmaceuticals Reports On Clinical Program Status And 2012 First Quarter Results
7. Lexicon to Provide First Quarter 2012 Financial Results
8. STAAR Surgical Provides Outlook On Second Quarter 2012 Financial Results
9. Johnson & Johnson Provides Notice Of Proposed Settlement Of Shareholder Derivative Actions, Final Settlement Hearing, And Right To Appear
10. Young Innovations, Inc. Provides 2nd Quarter Conference Call Details
11. Anthera Pharmaceuticals Provides Additional Data from the Recently Completed PEARL-SC Study of Blisibimod in the Proposed Phase 3 Population
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)...  Maxor National Pharmacy Services, LLC ("Maxor"), a leading ... Leah Bailey as General Counsel.  Bailey will serve ... With more than 13 years of experience ... on health care, Bailey joins the Maxor team coming ... advised the PBM, Specialty, and Mail Order business areas ...
(Date:3/29/2017)... , March 29, 2017  Designers of primary cell ... solution size by 50% and extend battery life with ... management integrated circuit (PMIC) from Maxim Integrated Products, Inc. ... a low input voltage of just 0.7V for new ... Silver Oxide, as well as the more common Alkaline ...
(Date:3/29/2017)... Michigan , USA, March 29, 2017 ... Company that Cares by People magazine, in partnership with ... of 50 companies on the list. This list highlights ... that have succeeded in business while also demonstrating respect, ... the environment.  To determine the companies ...
Breaking Medicine Technology:
(Date:3/29/2017)... Md., and MINNETONKA, Minn. (PRWEB) , ... March ... ... the development of medical office buildings (MOBs) and other outpatient facilities, and who ... project to look exclusively at those questions, Revista and Healthcare Real Estate Insights ...
(Date:3/29/2017)... Norwalk, CT (PRWEB) , ... March 29, 2017 , ... ... Valuing —on Thursday, April 20, 2017, at 1:00 PM ET. A recording of the ... of the Interactive Webinar Series. , Home health and hospice companies are still popular ...
(Date:3/29/2017)... PITTSBURGH, PA (PRWEB) , ... ... ... the eastern suburbs and South Hills of Pittsburgh now have easier access ... western Pennsylvania only by Allegheny Health Network (AHN). Orthopaedic surgeons at Forbes ...
(Date:3/29/2017)... ... ... VisualSP has helped over 1.5 million SharePoint users learn the content management system ... Help System for SharePoint was at the farm level. Enterprises using SharePoint Online in ... The company recently released a modified version of the Help System, VisualSP for Site ...
(Date:3/28/2017)... ... March 28, 2017 , ... ... first technology to directly address the resolution to globally reduce the harmful use ... patented compound of FDA and TTB approved ingredients that when infused into alcohol, ...
Breaking Medicine News(10 mins):